

# Diabetes Mellitus and Cognition

## Pathway Analysis in the MEMENTO Cohort

Eric Frison, MD, PhD, Cecile Proust-Lima, PhD, Jean-Francois Mangin, PhD, Marie-Odile Habert, MD, PhD, Stephanie Bombois, MD, PhD, Pierre-Jean Ousset, MD, PhD, Florence Pasquier, MD, PhD, Olivier Hanon, MD, PhD, Claire Paquet, MD, PhD, Audrey Gabelle, MD, PhD, Mathieu Ceccaldi, MD, PhD, Cédric Annweiler, MD, PhD, Pierre Krolak-Salmon, MD, PhD, Yannick Béjot, MD, PhD, Catherine Belin, MD, PhD, David Wallon, MD, PhD, Mathilde Sauvee, MD, PhD, Emilie Beauvils, MD, PhD, Isabelle Bourdel-Marchasson, MD, PhD, Isabelle Jalenques, MD, PhD, Marie Chupin, PhD, Geneviève Chêne, MD, PhD,\* and Carole Dufouil, PhD\*, on behalf of the MEMENTO Cohort Study Group

### Correspondence

Dr. Dufouil  
carole.dufouil@  
u-bordeaux.fr

*Neurology*® 2021;97:e836-e848. doi:10.1212/WNL.0000000000012440

## Abstract

### Objective

To assess the role of biomarkers of Alzheimer disease (AD), neurodegeneration, and small vessel disease (SVD) as mediators in the association between diabetes mellitus and cognition.

### Methods

The study sample was derived from MEMENTO, a cohort of French adults recruited in memory clinics and screened for either isolated subjective cognitive complaints or mild cognitive impairment. Diabetes was defined based on blood glucose assessment, use of antidiabetic agent, or self-report. We used structural equation modeling to assess whether latent variables of AD pathology (PET mean amyloid uptake,  $A\beta_{42}/A\beta_{40}$  ratio, and CSF phosphorylated tau), SVD (white matter hyperintensities volume and visual grading), and neurodegeneration (mean cortical thickness, brain parenchymal fraction, hippocampal volume, and mean fluorodeoxyglucose uptake) mediate the association between diabetes and a latent variable of cognition (5 neuropsychological tests), adjusting for potential confounders.

### Results

There were 254 (11.1%) participants with diabetes among 2,288 participants (median age 71.6 years; 61.8% women). The association between diabetes and lower cognition was significantly mediated by higher neurodegeneration (standardized indirect effect:  $-0.061$ , 95% confidence interval:  $-0.089$ ,  $-0.032$ ), but not mediated by SVD and AD markers. Results were similar when considering latent variables of memory or executive functioning.

\*These authors contributed equally to this work as co-senior authors.

From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épineuse, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distal (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chaumié Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Département de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

MEMENTO Cohort Study Group coinvestigators are listed at [lww.com/WNL/B459](https://www.lww.com/WNL/B459).

The Article Processing Charge was funded by INSERM.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

## Glossary

A $\beta$ 42 =  $\beta$ -amyloid 42 peptide; AD = Alzheimer disease; CFI = Comparative Fit Index; CI = confidence interval; FCSRT = Free and Cued Selective Reminding Test; FDG = fluorodeoxyglucose; MMSE = Mini-Mental State Examination; RMSEA = robust root mean square error of approximation; ROI = region of interest; SRMR = standardized root mean square residual; SUVR = standard uptake value ratio; SVD = small vessel disease; TLI = Tucker-Lewis Index; TMT = Trail Making Test; WMH = white matter hyperintensity.

## Conclusion

In a large clinical cohort in the elderly, diabetes is associated with lower cognition through neurodegeneration, independently of SVD and AD biomarkers.

Type 2 diabetes is a risk factor for cognitive decline and dementia.<sup>1,2</sup> Several underlying mechanisms could be involved, such as chronic hyperglycemia leading to advanced glycation end products, atherosclerosis, and subsequent cerebrovascular lesions.<sup>3-5</sup> Insulin dysregulation, including insulin resistance and insulin deficiency, may promote cerebral hypometabolism<sup>6</sup> and amyloid and tau pathologies, hallmarks of Alzheimer disease (AD).<sup>7</sup> Diabetes has also been associated with brain structural modifications such as cerebral atrophy and cerebrovascular lesions.<sup>8-10</sup> Moreover, whereas diabetes is associated with cerebral hypometabolism,<sup>11,12</sup> results are conflicting regarding its association with amyloid and tau pathology, whether measured in the brain (PET) or in CSF.<sup>11,13,14</sup>

Previous studies have suggested a mediating role of neurodegeneration and small vessel disease (SVD) biomarkers on the association between diabetes and cognition.<sup>15-17</sup> However, the mediating role of AD-specific lesions (amyloid plaques and neurofibrillary tangles) and the correlation between those different brain features have not been considered so far.

We estimated the mediating effect of biomarkers of AD, neurodegeneration, and SVD in the association between diabetes and cognition in older adults without dementia recruited from French memory clinics.

## Methods

### The MEMENTO Cohort

The MEMENTO cohort is a clinic-based study of patients presenting with a large variety of cognitive symptoms or subjective cognitive complaints, who were enrolled between April 2011 and June 2014, within the French national network of university hospital-based memory clinics.<sup>18</sup> At inclusion, participants presented with (1) mild cognitive impairment, performing 1 SD worse than the mean of the participant's own age, sex, and education-level group, in one or more cognitive domains, this deviation being identified for the first time through cognitive tests performed recently (less than 6 months preceding screening phase); or (2) isolated cognitive

complaints, if participants had subjective cognitive complaint (assessed through visual analogic scale), without any objective cognitive deficit as defined previously, while 60 years or older. All participants had a Clinical Dementia Rating scale<sup>19</sup> score  $\leq 0.5$ . Main exclusion criteria have been described elsewhere.<sup>22</sup> All examinations (including neuropsychological battery administration, clinical examinations, brain MRI, CSF samples, and fluorodeoxyglucose [FDG] and amyloid PET) followed standardized procedures.<sup>18</sup>

Among the 2,323 participants included in the MEMENTO cohort, 2,288 participants from 26 study centers were included in this analysis after exclusion of participants with missing data on diabetes status ( $n = 35$ ).

### Standard Protocol Approvals, Registrations, and Patient Consents

This study was performed in accordance with the Declaration of Helsinki. All participants provided written informed consent. The MEMENTO cohort protocol has been approved by the local ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III; approval number 2010-A01394-35) and was registered in ClinicalTrials.gov (Identifier: NCT01926249).

### Diabetes Definition

Participants were classified as having diabetes at baseline visit either in presence of fasting blood glucose  $\geq 7$  mmol/L ( $\geq 126$  mg/dL) or nonfasting blood glucose  $\geq 11.1$  mmol/L ( $\geq 200$  mg/dL) or antidiabetic drug intake (Anatomical Therapeutic Chemical classification system: code A10A "insulins and analogues" and code A10B "blood glucose lowering drugs, excl. insulins") or self-reported history of diabetes.

### Neuropsychological Evaluation

A full neuropsychological test battery was administered to participants.<sup>18</sup> Global cognition was assessed by Mini-Mental State Examination (MMSE),<sup>20</sup> long-term memory was assessed by Free and Cued Selective Reminding Test (FCSRT),<sup>21</sup> semantic verbal fluency via animal words,<sup>22</sup> visuo-spatial abilities by Rey-Osterrieth Complex Figure Test,<sup>23</sup> and attention and executive functions by Trail Making Test (TMT) A and B.<sup>24</sup>

## Biomarkers Assessment

### MRI

As part of the inclusion criteria, participants had to agree to undergo brain MRI. Brain magnetic resonance images were acquired after a standardization of the imaging processes and coordinated by CATI ([cati-neuroimaging.com](http://cati-neuroimaging.com)), a neuroimaging platform dedicated to multicenter studies.<sup>25</sup> Full details are described elsewhere.<sup>18</sup> Briefly, MRI machines of 1.5T and 3T were used across centers using harmonized protocols. All MRI scans acquired were then centralized, quality checked, and postprocessed to obtain standardized measurements for each participant. Whole-brain, gray matter, and white matter volumes were assessed with Statistical Parametric Mapping 8,<sup>26</sup> hippocampal volumes with the SACHA software,<sup>27</sup> and mean cortical thickness of each hemisphere with FreeSurfer 5.3 averaged in the region of interest (ROI) of the Desikan-Killiany atlas.<sup>28</sup> White matter lesion volumetry was performed using WHASA software<sup>29</sup> complemented by a centralized visual assessment by a trained rater using the Fazekas and Schmidt scale.<sup>30</sup>

### FDG-PET

<sup>18</sup>F-FDG-PET was offered to all participants but was not mandatory. PET images were acquired after a standardization of the acquisition and reconstruction imaging parameters, coordinated by CATI.<sup>31</sup> After a centralized quality check and postprocessing performed by CATI, the following measures were obtained: mean FDG-PET uptake for the ROIs of the Automated Anatomical Labeling atlas relative to the pons reference region,<sup>32</sup> including partial volume correction, and mean FDG-PET uptake for a set of AD-specific ROIs inferred from the Alzheimer's Disease Neuroimaging Initiative database,<sup>33</sup> expressed as standard uptake value ratios (SUVs).

### PET Amyloid Imaging

PET amyloid imaging was available for 643 participants of the analytical sample, using either <sup>18</sup>F-florbetapir (Amyvid, Eli Lilly) (n = 437) or <sup>18</sup>F-flutemetamol (Vizamyl, GE Healthcare) (n = 206) radioligands. Mean brain amyloid SUVR was computed, harmonized across the radioligands,<sup>34</sup> and used for the current study.

### CSF Sampling

Lumbar puncture was offered to all participants but was not mandatory, and CSF centralized measurements of  $\beta$ -amyloid 42 peptide ( $A\beta_{42}$ ),  $A\beta_{40}$ , total tau, and phosphorylated tau levels were performed using the standardized INNOTEST sandwich ELISA (Fujirebio).

### Potential Confounding Factors

Sociodemographic information recorded at baseline included age, sex, and education (low education defined as no or primary school, intermediate education defined as secondary school or high school, and high education defined as university). Lifestyle factors included smoking status (never, former, and current smoker) and current alcohol consumption (none,

$\leq 1$  drink/day, and  $>1$  drink/day). Hypertension was defined as antihypertensive drug intake or mean of 3 blood pressure measurements either  $\geq 140$  mm Hg for systolic blood pressure or  $\geq 90$  mm Hg for diastolic blood pressure. Dyslipidemia was defined by plasma cholesterol  $>6.24$  mmol/L or use of any lipid-lowering drugs. Body mass index was categorized as  $<20$  kg/m<sup>2</sup>, 20–25 kg/m<sup>2</sup>, 25.1–29.9 kg/m<sup>2</sup>, and  $\geq 30$  kg/m<sup>2</sup>. History of cardiovascular disease was defined as a self-reported history of myocardial infarction, angina pectoris, coronary artery, or peripheral artery disease. History of stroke was self-reported. Depression was assessed with the Neuro-psychiatric Inventory–Clinician.<sup>35</sup> APOE  $\epsilon 2$ ,  $\epsilon 3$ , or  $\epsilon 4$  alleles were determined for all participants by KBiosciences ([kbioscience.co.uk](http://kbioscience.co.uk)) as described elsewhere.<sup>18</sup> APOE  $\epsilon 4$  status was defined as presence of at least one  $\epsilon 4$  allele.

### Statistical Analyses

Baseline characteristics were compared according to baseline diabetic status for the analytical sample. We used  $\chi^2$  test (or Fisher exact test when appropriate) and Student *t* test (or nonparametric Mann-Whitney-Wilcoxon test when appropriate) for categorical and continuous variables comparisons, respectively.

Brain parenchymal fraction was computed as the sum of gray matter and white matter volumes divided by total intracranial volume. Total hippocampal volume was computed as the sum of left and right hippocampal volumes. White matter hyperintensity (WMH) volume and hippocampal volume were adjusted for total intracranial volume using the residual approach.<sup>36</sup> Mean FDG uptake across the brain was used.

Structural equation modeling<sup>37</sup> was used to examine a potential mediating role of biomarkers respectively of AD, SVD, and neurodegeneration in the association between diabetes and cognition. Structural equation modeling was preferred over standard regression modeling for its ability to directly focus the mediation analysis on the dimensions of interest (here cognition, SVD, AD, and neurodegeneration), and to define each dimension from several noisy observed indicators. The observed indicators of the 4 latent variables of interest, namely AD pathology, SVD, neurodegeneration, and cognition, are listed in Table 1. They were determined from the literature and validated in preliminary separated structural equation modeling analyses. Correlated residuals were assumed between left and right cortical thicknesses and between TMT A and TMT B scores to account for a potential common source of measurement error. Mean brain amyloid SUVR was normalized using a logarithmic transformation and then standardized (*z* score) by radioligand. The relationships between diabetes, potential confounders, and latent variables of AD pathology, neurodegeneration, SVD, and cognition were modeled in the structural linear regressions. For ease of interpretation, the 4 latent variables were standardized (mean 0, variance 1) so that 1 unit corresponds to the SD of a given dimension. The indirect effects of diabetes on cognition through the latent dimensions were estimated with their 95%

confidence interval (CI), using path analysis technique.<sup>37</sup> All linear regressions of mediators and cognition were adjusted for the following potential confounding factors: age, sex, education (high education vs low and intermediate), smoking status (current smoker vs never or former smoker), alcohol consumption (>1 drink/day vs ≤1 drink/day), hypertension, dyslipidemia, obesity (≥30 kg/m<sup>2</sup>), and APOE genotype (ε4 carrier vs ε4 noncarrier). Missing values for observed indicators of latent variables and for confounding factors were handled using a full information maximum likelihood approach, assuming missingness at random. The multicentric nature of the data was accounted for and Huber-White robust standard errors were reported to correct for the potential intracenter correlation.<sup>38</sup> The general goodness of fit was evaluated using robust Tucker-Lewis Index (TLI), robust Comparative Fit Index (CFI), robust root mean square error of approximation (RMSEA) and its 90% CI, *p* value for test of close fit (null hypothesis RMSEA <0.05), and standardized root mean square residual (SRMR) with cutoffs recommended in the literature.<sup>39</sup>

Several sensitivity analyses were performed. First, we used a different definition of “diabetes” by excluding a self-reported history of diabetes. Second, additional baseline characteristics associated with availability of MRI, FDG-TEP, amyloid-PET, and CSF data (living alone, Clinical Dementia Rating scale score, prevalent dementia, depression, stroke history, cardiovascular

history, and physical activity expressed as metabolic equivalent of task minutes per week; Table 2) were used as auxiliary variables in the estimation process under FIML to strengthen the missing at random assumption. Third, as the mediation analysis framework makes the implicit assumption that mediators (i.e., AD pathology, SVD, and neurodegeneration) are anterior to the outcome (i.e., cognition), we tried to preserve this assumption by excluding biomarkers measurements performed more than 6 months after cognitive assessments. Fourth, as CSF biomarkers are prone to variability whereas brain biomarkers are indicators of accumulated burden of lesions,<sup>40</sup> we performed a sensitivity analysis using only brain amyloid load as indicator of the latent variable for AD pathology. Finally, we also compared the results with those obtained when considering interactions between diabetes and each mediator in the main adjusted model, as recommended for mediation analysis.<sup>41</sup>

We also explored the mediating pathways in the association of diabetes with specific cognitive domains in separate models: a latent variable for memory (indicators: total free recall score and verbal fluency) and a latent variable for executive functioning (indicators: TMT A and TMT B scores).

Analyses were conducted using SAS v9.3 (SAS Institute Inc.), and R version 3.5.1<sup>42</sup> with the lavaan package for structural equation modeling analysis.<sup>38</sup>

**Table 1** Observed Indicators for Latent Dimensions Variables

Latent variables	Observed indicators	Data available, n (%)
<b>Small vessel disease</b>	White matter hyperintensities volume	1,884 (80.6)
	Fazekas scale scores for paraventricular white matter hyperintensities	2,145 (93.8)
	Fazekas scale scores for deep white matter hyperintensities	2,145 (93.8)
<b>Alzheimer disease pathology</b>	Mean brain amyloid uptake	643 (28.1)
	CSF Aβ <sub>42</sub> /Aβ <sub>40</sub> ratio	400 (17.5)
	CSF phosphorylated tau	408 (17.8)
<b>Neurodegeneration</b>	Mean right cortical thickness	2,106 (92.0)
	Mean left cortical thickness	2,106 (92.0)
	Brain parenchymal fraction	2,103 (91.9)
	Hippocampal volume	2,061 (90.1)
	Mean brain FDG uptake	1,308 (57.2)
<b>Cognition</b>	FCSRT total free recall score	2,269 (99.2)
	TMT A (seconds/correct move)	2,265 (99.0)
	TMT B (seconds/correct move)	2,192 (95.8)
	Rey Complex Figure Test, 3-minute copy score	2,125 (92.9)
	Verbal fluency (number of animals produced)	2,245 (98.1)

Abbreviations: FCSRT = Free and Cued Selective Reminding Test; TMT = Trail Making Test.

**Table 2** Baseline Characteristics Associated With the Availability of MRI, FDG-PET, Amyloid-PET, and CSF Data: MEMENTO Study, France (n = 2,288)

	Available data		<i>p</i> <sup>a</sup>
	No	Yes	
<b>MRI, n</b>	130	2,158	
<b>Cardiovascular history</b>	20 (15.4)	185 (8.6)	0.008
<b>MMSE score</b>	27.4 (2.2)	27.9 (1.9)	0.001
<b>FCSRT total free recall score</b>	24.3 (9.2)	26.1 (8.2)	0.01
<b>FDG-PET, n</b>	980	1,308	
<b>Female sex</b>	648 (66.1)	765 (58.5)	<0.001
<b>Current alcohol consumption:</b>			0.006
<b>None</b>	352 (37.1)	399 (30.8)	
<b>≤1 drink/d</b>	412 (43.5)	604 (46.7)	
<b>&gt;1 drink/d</b>	184 (19.4)	291 (22.5)	
<b>Dyslipidemia</b>	402 (55.0)	480 (46.3)	<0.001
<b>MMSE score</b>	27.8 (2.0)	28.0 (1.9)	0.009
<b>TMT A (seconds/correct move)</b>	2.1 (1.0)	2.0 (0.9)	0.005
<b>TMT B (seconds/correct move)</b>	5.2 (3.6)	4.9 (3.2)	0.02
<b>Rey Complex Figure Test, 3-minute copy score</b>	14.5 (7.1)	15.6 (6.9)	<0.001
<b>Verbal fluency, animals (number of words produced)</b>	27.7 (8.7)	28.8 (8.7)	0.006
<b>Amyloid-PET, n</b>	1,645	643	
<b>Current alcohol consumption</b>			<0.001
<b>None</b>	584 (36.4)	167 (26.2)	
<b>≤1 drink/d</b>	713 (44.5)	303 (47.5)	
<b>&gt;1 drink/d</b>	307 (19.1)	168 (26.3)	
<b>Diabetes</b>	201 (12.2)	53 (8.2)	0.007
<b>Dyslipidemia</b>	642 (52.8)	240 (43.6)	<0.001
<b>Depression</b>	677 (41.2)	212 (33.0)	<0.001
<b>Clinical Dementia Rating scale</b>			<0.001
<b>0</b>	540 (33.0)	383 (59.8)	
<b>0.5</b>	1,096 (67.0)	258 (40.2)	
<b>MMSE score</b>	27.7 (2.1)	28.3 (1.5)	<0.001
<b>FCSRT total free recall score</b>	25.0 (8.6)	28.4 (6.9)	<0.001
<b>TMT A (seconds/correct move)</b>	2.1 (1.0)	1.9 (0.7)	<0.001
<b>TMT B (seconds/correct move)</b>	5.3 (3.6)	4.5 (2.7)	<0.001
<b>Rey Complex Figure Test, 3-minute copy score</b>	14.7 (7.1)	16.4 (6.6)	<0.001
<b>Verbal fluency, animals (number of words produced)</b>	27.5 (8.8)	30.3 (8.2)	<0.001
<b>CSF, n</b>	1,877	411	
<b>Age, y</b>	71.3 (8.6)	68.8 (8.8)	<0.001
<b>Female sex</b>	1,197 (63.8)	216 (52.6)	<0.001

Continued

**Table 2** Baseline Characteristics Associated With the Availability of MRI, FDG-PET, Amyloid-PET, and CSF Data: MEMENTO Study, France (n = 2,288) (continued)

	Available data		p <sup>a</sup>
	No	Yes	
Living alone	602 (32.4)	101 (24.6)	0.002
Physical activity, MET-h/wk	52.2 (47.2)	59.7 (52.9)	0.01
Clinical Dementia Rating scale			0.02
0	777 (41.6)	146 (35.5)	
0.5	1,089 (58.4)	265 (64.5)	
APOE ε4 carrier	501 (28.0)	155 (38.9)	<0.001
MMSE	27.9 (1.9)	27.7 (2.0)	0.001
FCSRT total free recall score	26.3 (8.2)	24.6 (8.8)	<0.001
Verbal fluency, animals (number of words produced)	28.4 (8.7)	27.9 (8.9)	0.04

Abbreviations: FCSRT = Free and Cued Selective Reminding Test; MET = metabolic equivalent of task; MMSE = Mini-Mental State Examination; TMT = Trail Making Test.

<sup>a</sup> p Values for comparison using t tests for quantitative variables and  $\chi^2$  test or Fisher test for qualitative variables. Comparisons for cognitive tests were adjusted for age, sex, and education.

## Data Availability

Anonymized data will be shared by request from any qualified investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation.

## Results

### Baseline Description

Compared to participants without diabetes at baseline, participants with diabetes (254 [11.1%]) were more likely to be men and to have lower education level. They were also more likely to have hypertension, dyslipidemia, obesity, and history of cardiovascular disease or stroke. Participants with diabetes had on average lower performances on executive functions and attention, memory, and semantic verbal fluency (Table 3).

At baseline, 65.3% of participants with diabetes were taking antidiabetic medications (oral antidiabetic agents, 57.5%; insulin, 13.8%). Diabetes status was solely based on self-report in 60 (23.6%) of the diabetic participants. The median self-reported duration of diabetes was 10.0 years (interquartile range, 4.9–19.4 years).

### Diabetes, Latent Biomarkers, and Latent Cognition

The model fit was adequate according to the recommended cutoffs: robust CFI = 0.951, robust TLI = 0.926, robust RMSEA = 0.040 (90% CI 0.037, 0.042), p value for test of close fit = 1.00, and SRMR = 0.038. Associations between diabetes, AD pathology, SVD, neurodegeneration and

cognition are presented in the Figure. Presence of diabetes was significantly associated with higher neurodegeneration but was not significantly associated with AD pathology and SVD. Higher levels of SVD, neurodegeneration, and AD pathology were independently associated with lower cognition. Once adjusted for neurodegeneration, AD pathology, and SVD, there was no direct effect of diabetes on cognition (standardized  $\beta$  = 0.023; 95% CI –0.030, 0.076;  $p$  = 0.40). Association between diabetes and lower cognition was mainly mediated by higher neurodegeneration (standardized  $\beta$  = –0.061; 95% CI –0.089, –0.032;  $p$  < 0.001). The indirect effect of diabetes on cognition via SVD and AD pathology was not statistically significant (standardized  $\beta$  = 0.000; 95% CI –0.004, 0.004;  $p$  = 0.98 and standardized  $\beta$  = –0.013; 95% CI –0.040, 0.015;  $p$  = 0.38, respectively). In complementary analyses considering specific cognitive functions, associations between diabetes and lower memory or lower executive functioning were also mainly mediated by higher neurodegeneration (standardized  $\beta$  = –0.058; 95% CI –0.088, –0.029;  $p$  < 0.001 and standardized  $\beta$  = –0.034; 95% CI –0.051, –0.016;  $p$  < 0.001, respectively) (Table 4).

### Sensitivity Analyses

Results were similar when excluding self-reported history from the definition of diabetes, when adding auxiliary variables to the estimation process, or when excluding delayed measures of biomarkers (Table 5). When using only brain amyloid load as indicator of the latent variable for AD pathology, the indirect pathway linking diabetes to lower cognition through higher neurodegeneration was of similar magnitude (standardized  $\beta$  = –0.066; 95% CI –0.097, –0.034;  $p$  < 0.001). Diabetes was significantly associated with higher AD pathology (standardized  $\beta$  = 0.107; 95% CI 0.021, 0.193;

**Table 3** Baseline Characteristics According to Diabetes: MEMENTO Cohort, France (n = 2,288)

	Diabetes		<i>p</i> <sup>a</sup>
	No (n = 2,034)	Yes (n = 254)	
Age, y	70.9 (8.8)	70.8 (7.9)	0.80
Female sex	1,302 (64.0)	111 (43.7)	<0.001
Education			0.02
Low	487 (23.9)	71 (28.0)	
Intermediate	722 (35.5)	103 (40.6)	
High	823 (40.5)	80 (31.5)	
Smoking status			0.05
Never	1,191 (59.0)	137 (54.8)	
Former	676 (33.5)	101 (40.4)	
Current	151 (7.5)	12 (4.8)	
Current alcohol consumption			0.17
No	658 (33.0)	93 (37.8)	
Up to 1 drink/day	918 (46.0)	98 (39.8)	
>1 drink/day	420 (21.0)	55 (22.4)	
Body mass index, kg/m <sup>2</sup>			<0.001
<20	145 (7.3)	6 (2.4)	
20–25	910 (45.7)	68 (27.6)	
25.1–29.9	712 (35.8)	92 (37.4)	
≥30	223 (11.2)	80 (32.5)	
Hypertension	1,135 (59.8)	188 (77.4)	<0.001
Dyslipidemia	761 (48.9)	127 (60.5)	0.002
Self-reported cardiovascular history	156 (7.7)	49 (19.3)	<0.001
Self-reported stroke history	76 (3.7)	16 (6.3)	0.05
Depression	791 (38.9)	98 (38.6)	0.92
APOE ε4 carrier	596 (30.6)	60 (24.6)	0.05
Cognitive tests			
MMSE score	28.0 (1.9)	27.6 (2)	0.03 <sup>b</sup>
FCSRT total free recall score	26.2 (8.4)	24.2 (7.4)	0.03 <sup>b</sup>
TMT A (seconds/correct move)	2.05 (0.94)	2.16 (0.88)	0.02 <sup>c</sup>
TMT B (seconds/correct move)	4.97 (3.39)	5.57 (3.41)	<0.001 <sup>d</sup>
Rey Complex Figure Test, 3-minute copy score	15.1 (7.0)	15.5 (7.0)	0.89 <sup>b</sup>
Verbal fluency (number of animals produced)	28.5 (8.7)	26.9 (8.7)	0.04 <sup>b</sup>

Abbreviations: FCSRT = Free and Cued Selective Reminding Test; MMSE = Mini-Mental State Examination; TMT = Trail Making Test.

Missing data: education, 2; smoking status, 20; alcohol consumption, 46; body mass index, 52; hypertension, 148; dyslipidemia, 521; APOE genotype, 98; MMSE, 6; FCSRT, 19; TMT A, 23; TMT B, 96; Rey Complex Figure Test, 163; verbal fluency, 43.


<sup>a</sup> *p* Values for comparison using *t* tests for quantitative variables and  $\chi^2$  test or Fisher test for qualitative variables, except when stated otherwise.

<sup>b</sup> *p* Values for comparison using linear regression modeling adjusted on age, sex, and education.

<sup>c</sup> *p* Value for comparison of log-transformed values of TMT A, adjusted on age, sex, and education.

<sup>d</sup> *p* Value for comparison of log-transformed values of TMT B, adjusted on age, sex, and education.

**Figure** Structural Equation Model for the Association Between Diabetes, Small Vessel Disease, Neurodegeneration, Alzheimer Disease (AD) Biomarkers, and Cognition



Latent variables of interest are indicated in ovals and observed variables in rectangles. Directed arrows represent linear regressions. Bidirectional arrows represent correlations. Standardized regression coefficient estimates are presented with their 95% confidence interval. Solid lines indicate statistically significant associations and correlations at the 5% level. Dotted lines indicate non-statistically significant associations and correlations at the 5% level. Adjustment covariates and their directed arrows to small vessel disease, neurodegeneration, AD biomarkers, and cognition are represented in gray. For readiness, the observed indicators defining each latent variable (listed in Table 1) and residual variances for all variables were omitted. \* $p < 0.001$ .

$p = 0.01$ ), and higher AD pathology was significantly associated with lower cognition (standardized  $\beta = -0.144$ ; 95% CI  $-0.248, -0.039$ ;  $p = 0.007$ ). The indirect pathway linking diabetes to lower cognition through AD pathology remained non-statistically significant (standardized  $\beta = -0.015$ ; 95% CI  $-0.033, 0.002$ ;  $p = 0.08$ ). When considering interaction between diabetes and each intermediate latent variable, the indirect effects of diabetes on cognition via neurodegeneration (standardized  $\beta = -0.059$ ; 95% CI  $-0.089, -0.030$ ;  $p < 0.001$ ), AD pathology (standardized  $\beta = -0.011$ ; 95% CI  $-0.034, 0.012$ ;  $p = 0.34$ ), and SVD (standardized  $\beta = -0.001$ ; 95% CI  $-0.006, 0.003$ ;  $p = 0.54$ ) remained virtually the same.

## Discussion

In a cross-sectional analysis of a large clinical cohort of participants with either isolated cognitive complaints or mild cognitive impairment, we report that the deleterious effect of diabetes on cognitive performance is mainly mediated through markers of neurodegeneration whereas AD pathology (amyloid, p-tau) or SVD pathology do not seem to play a major role.

The association between diabetes and markers of neurodegeneration such as brain atrophy<sup>8,12,13,43</sup> and brain hypometabolism<sup>11,12</sup> has been consistently reported in cross-

sectional studies. While diabetes is a risk factor for vascular disease and stroke, its association with subclinical cerebrovascular lesions (silent brain infarcts, WMH, cerebral microbleeds) is uncertain.<sup>44</sup> In the present study, diabetes was not associated with SVD, even though participants with diabetes had more frequent self-reported history of stroke.

The mediating role of neurodegeneration and SVD in the association between diabetes and cognition has already been investigated in several studies. In a sample of 4,206 older adults of the Age, Gene/Environment Susceptibility-Reykjavik Study (mean age 76 years, 11% with diabetes), MRI markers of neurodegeneration (gray matter, normal white matter, and total brain tissue volumes) and SVD (cortical infarcts, subcortical infarcts, white matter lesions, and cerebral microbleeds) significantly mediated the cross-sectional association of diabetes with lower processing speed and executive function.<sup>15</sup> In a longitudinal analysis on 817 participants from the Alzheimer's Disease Neuroimaging Initiative cohort (mean age 75 years, 15% with diabetes), the effect of diabetes on cognitive decline up to 60 months (mean follow-up time, 30 months) was significantly mediated by baseline cortical thickness.<sup>17</sup> Similarly, in a sample of 448 older adults of the Swedish National Study on Aging and Care in Kungsholmen (mean age at baseline, 72 years), a higher cardiovascular burden, including diabetes as a component, was associated



**Table 4** Association Between Diabetes, Biomarkers of Small Vessel Disease (SVD), Neurodegeneration and Alzheimer Disease (AD), and Specific Cognitive Domains: Structural Equation Model

	Latent variable of memory		Latent variable of executive functioning	
	Standardized (95% CI)	p Value	Standardized (95% CI)	p Value
<b>Direct effect of diabetes on:</b>				
SVD	0.001 (−0.035; 0.037)	0.95	0.001 (−0.034; 0.037)	0.94
AD pathology	0.047 (−0.059; 0.153)	0.38	0.053 (−0.049; 0.155)	0.31
Neurodegeneration	0.108 (0.071; 0.145)	<0.001	0.110 (0.074; 0.146)	<0.001
<b>Direct effect of:</b>				
Diabetes on cognition	0.016 (−0.037; 0.069)	0.55	−0.017 (−0.070; 0.036)	0.53
SVD on cognition	−0.104 (−0.169; −0.040)	0.001	−0.094 (−0.163; −0.024)	0.008
Neurodegeneration on cognition	−0.542 (−0.737; −0.346)	<0.001	−0.306 (−0.441; −0.171)	<0.001
AD pathology on cognition	−0.282 (−0.421; −0.144)	<0.001	−0.169 (−0.269; −0.068)	0.001
<b>Correlation between:</b>				
SVD and AD pathology	0.159 (0.064; 0.253)	<0.001	0.151 (0.057; 0.245)	0.001
SVD and neurodegeneration	0.038 (−0.056; 0.133)	0.42	0.023 (−0.077; 0.123)	0.65
AD and neurodegeneration	0.257 (0.116; 0.398)	<0.001	0.256 (0.128; 0.384)	<0.001
<b>Indirect effect of diabetes on cognition:</b>				
Through SVD	0.000 (−0.004; 0.004)	0.95	0.000 (−0.003; 0.003)	0.94
Through AD pathology	−0.013 (−0.042; 0.015)	0.36	−0.009 (−0.027; 0.010)	0.34
Through neurodegeneration	−0.058 (−0.088; −0.029)	<0.001	−0.034 (−0.051; −0.016)	<0.001
<b>Model fit indices</b>				
Robust CFI	0.963		0.974	
Robust TLI	0.937		0.956	
Robust RSMEA (90% CI)	0.038 (0.035; 0.041)		0.032 (0.029; 0.035)	
p Value for test of close fit	1.00		1.00	
SRMR	0.035		0.035	

Abbreviations: CI = confidence interval; CFI = comparative fit index; RSMEA = root mean square error of approximation; SRMR = standardized root mean square residual; TLI = Tucker-Lewis Index.

with a faster MMSE decline over 9 years, this effect being largely mediated by brain MRI markers of atrophy (volumes of total gray matter, ventricles, and hippocampus) and SVD (volume of WMHs).<sup>16</sup> Nevertheless, none of those studies accounted for AD biomarkers, unlike the present study.

Insulin resistance and associated insulin signaling impairment promote A $\beta$  accumulation and tau phosphorylation.<sup>7</sup> However, no association between diabetes and amyloid and tau biomarkers was reported in previous studies.<sup>11,13,45</sup> In the present study, diabetes was associated with higher brain amyloid load measured on PET imaging, but diabetes was not associated with the latent variable of AD pathology, which included CSF biomarkers of amyloid and tau. This discrepancy between brain and CSF biomarkers can partly be

explained by the variability of CSF biomarkers, whereas brain biomarkers are indicators of accumulated lesions.

Although it needs to be replicated in longitudinal studies, our finding that neurodegeneration mediates the association between diabetes and cognitive performance, independently of biomarkers of AD and SVD, supports the hypothesis of a direct role of diabetes-related insulin resistance in the development of cognitive impairment in older adults with diabetes. Indeed, insulin also plays an important role in neuronal synaptic plasticity and facilitates learning and memory in humans<sup>4</sup> and, therefore, impaired insulin signaling could directly contribute to neuronal dysfunction and degeneration. As impaired insulin signaling has also been linked to promotion of amyloid- $\beta$  accumulation and tau hyperphosphorylation,<sup>7</sup> brain insulin

**Table 5** Association Between Diabetes, Biomarkers, and Global Cognition: Sensitivity Analyses

	Excluding self-reported history of diabetes		Adding auxiliary variables		Excluding delayed biomarker measurements (>6 months)		Using only brain biomarkers as indicators	
	Standardized estimate (95% CI)	p Value	Standardized estimate (95% CI)	p Value	Standardized estimate (95% CI)	p Value	Standardized estimate (95% CI)	p Value
<b>Direct effect of diabetes on:</b>								
<b>SVD</b>	-0.006 (-0.045; 0.033)	0.77	0.002 (-0.035; 0.038)	0.92	0.006 (-0.031; 0.043)	0.75	0.001 (-0.035; 0.036)	0.97
<b>AD pathology</b>	0.049 (-0.046; 0.143)	0.31	0.044 (-0.067; 0.155)	0.44	-0.007 (-0.172; 0.159)	0.94	0.107 (0.021; 0.193)	0.01
<b>Neurodegeneration</b>	0.084 (0.049; 0.121)	<0.001	0.109 (0.072; 0.146)	<0.001	0.106 (0.068; 0.144)	<0.001	0.108 (0.071; 0.144)	<0.001
<b>Direct effect on cognition of:</b>								
<b>Diabetes</b>	0.030 (-0.017; 0.076)	0.21	0.023 (-0.030; 0.077)	0.39	0.012 (-0.047; 0.072)	0.69	0.030 (-0.020; 0.080)	0.23
<b>SVD</b>	-0.114 (-0.185; -0.044)	<0.001	-0.113 (-0.183; -0.043)	0.001	-0.108 (-0.187; -0.029)	0.007	-0.131 (-0.201; -0.061)	<0.001
<b>Neurodegeneration</b>	-0.576 (-0.743; -0.408)	0.001	-0.565 (-0.731; -0.399)	<0.001	-0.601 (-0.765; -0.436)	<0.001	-0.609 (-0.777; -0.442)	<0.001
<b>AD pathology</b>	-0.273 (-0.391; -0.154)	<0.001	-0.275 (-0.403; -0.147)	<0.001	-0.285 (-0.459; -0.111)	0.001	-0.144 (-0.248; -0.039)	0.007
<b>Correlation between:</b>								
<b>SVD and AD pathology</b>	0.157 (0.060; 0.254)	0.002	0.163 (0.066; 0.260)	<0.001	0.161 (0.025; 0.298)	0.02	0.156 (0.054; 0.257)	0.003
<b>SVD and neurodegeneration</b>	0.040 (-0.053; 0.134)	0.39	0.038 (-0.133; 0.057)	0.43	0.039 (-0.056; 0.134)	0.42	0.039 (-0.056; 0.133)	0.42
<b>AD and neurodegeneration</b>	0.269 (0.130; 0.409)	<0.001	0.259 (0.127; 0.390)	<0.001	0.160 (0.004; 0.316)	0.04	0.236 (0.096; 0.376)	0.001
<b>Indirect effect of diabetes on cognition:</b>								
<b>Through SVD</b>	0.001 (-0.004; 0.005)	0.77	0.000 (-0.004; 0.004)	0.92	-0.001 (-0.005; 0.003)	0.75	0.000 (-0.005; 0.005)	0.97
<b>Through AD pathology</b>	-0.013 (-0.037; 0.011)	0.28	-0.012 (-0.042; 0.018)	0.42	0.002 (-0.046; 0.049)	0.93	-0.015 (-0.033; 0.002)	0.08
<b>Through neurodegeneration</b>	-0.048 (-0.075; -0.021)	<0.001	-0.061 (-0.091; -0.032)	<0.001	-0.064 (-0.093; -0.035)	<0.001	-0.066 (-0.097; -0.034)	<0.001
<b>Model fit indices</b>								
<b>Robust CFI</b>	0.951		0.951		0.948		0.953	
<b>Robust TLI</b>	0.926		0.926		0.921		0.924	
<b>Robust RSMEA (90% CI)</b>	0.040 (0.037; 0.042)		0.040 (0.037; 0.042)		0.040 (0.038; 0.043)		0.043 (0.040; 0.046)	
<b>p Value for test of close fit</b>	1.00		1.00		1.00		1.00	
<b>SRMR</b>	0.038		0.032		0.042		0.033	

Abbreviations: AD = Alzheimer disease; CFI = comparative fit index; CI = confidence interval; RSMEA = root mean square error of approximation; SRMR = standardized root mean square residual; SVD = small vessel disease; TLI = Tucker-Lewis Index.

resistance could be a therapeutic target in AD and related dementias. Several exploratory clinical trials have reported a beneficial effect on cognition of intranasal insulin for healthy participants and participants with diabetes, mild cognitive impairment, or AD,<sup>46</sup> and longer-term trials are ongoing.

The MEMENTO study has several strengths to answer the current objectives. First, a wide range of biomarkers was acquired in a highly standardized setting on more than 2,000 participants allowing a multidimensional assessment of brain aging and pathology biomarkers. Indeed, we were able to include simultaneously brain MRI, brain FDG-PET, amyloid-PET, and CSF data in a mediation analysis of the diabetes–cognition association, offering a unique insight on underlying mechanisms. Second, we were able to model brain biomarkers as latent variables in a structural equation modeling framework, accounting for measurement error of the indicators, and we were able to estimate direct and indirect effects of diabetes on several domains of cognition. Third, results were robust to several sensitivity analyses. There are also some limitations. First, the temporal relationship between diabetes, biomarkers, and cognition is not ensured by the cross-sectional design, and causality cannot be claimed. Nevertheless, we can hypothesize that diabetes preceded biomarkers measures in most participants with diabetes (duration was 4.9 years or more in 75% of participants with diabetes). We also modeled correlations between neurodegeneration, AD pathology, and SVD instead of directed relationships because the causal interpretation of their interrelations requires longitudinal data. Second, no tau-PET data were available to assess tau pathology, and we had to use CSF phosphorylated tau as a proxy for cerebral tau accumulation, assuming a strong correlation between both, as suggested by existing evidence.<sup>40</sup> Third, the analytical strategy relies on the assumption that data are missing at random. This assumption may be strong for CSF and PET-amyloid data, for which 70%–80% of data were missing. However, we used a broad range of baseline characteristics associated with availability of CSF and PET-amyloid data as auxiliary variables in the estimation process, thus making the missing-at-random assumption more plausible. We must also acknowledge the unavailability of data regarding past and current glucose control that prevented us from exploring whether diabetes control modified the explored relationships. Finally, the observed findings may not fully translate in the general older population, as participants in the MEMENTO study are adults with either isolated cognitive complaints or mild cognitive impairment who were seeking care in memory clinics.

The current results suggest that the detrimental effect of diabetes on cognition is mediated by neurodegeneration, independently of AD and SVD pathologies, in a population of older adults at risk for dementia. Longitudinal studies are needed to reinforce and confirm these findings.

## Acknowledgment

The MEMENTO cohort is sponsored by Bordeaux University Hospital (coordination: CIC1401-EC, Bordeaux) and was funded through research grants from the Fondation Plan Alzheimer (Alzheimer Plan 2008–2012), the French Ministry

of Research and Higher Education (Plan Maladies Neurodégénératives [2016–2020]). The MEMENTO cohort has received funding support from AVID, GE Healthcare, and FUJIREBIO through private–public partnerships. The Insight-PreAD substudy was promoted by INSERM in collaboration with the Institut du Cerveau et de la Moelle Épinière, Institut Hospitalo-Universitaire, and Pfizer and has received support within the “Investissement d’Avenir” (ANR-10-AIHU-06) program. Sponsor and funders were not involved in the study conduct, analysis, or interpretation of data.

## Study Funding

The authors report no targeted funding.

## Disclosure

The authors report no disclosures relevant to the manuscript. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

## Publication History

Received by *Neurology* December 6, 2020. Accepted in final form May 25, 2021.

## Appendix Authors

Name	Location	Contribution
<b>Eric Frison, MD, PhD</b>	Univ. Bordeaux, INSERM, UMR 1219, INSERM, CIC1401-EC; Pole de Sante Publique Centre Hospitalier Universitaire (CHU) de Bordeaux, France	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
<b>Cecile Proust-Lima, PhD</b>	Univ. Bordeaux, INSERM, UMR 1219, France	Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; analysis or interpretation of data
<b>Jean-Francois Mangin, PhD</b>	CATI Multicenter Neuroimaging Platform, Paris; Neurospin CEA Paris Saclay University, Gif-sur-Yvette, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design
<b>Marie-Odile Habert, MD, PhD</b>	CATI Multicenter Neuroimaging Platform; Sorbonne Université, CNRS, INSERM, Laboratoire d’Imagerie Biomédicale; AP-HP, Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design
<b>Stephanie Bombois, MD, PhD</b>	IM2A AP-HP INSERM UMR-S975 Groupe Hospitalier Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d’Alzheimer Institut du Cerveau et de la Moelle Épinière Sorbonne Université Paris, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Pierre-Jean Ousset, MD, PhD</b>	INSERM UMR1027, Université de Toulouse III Paul Sabatier, Toulouse, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data

## Appendix (continued)

Name	Location	Contribution
<b>Florence Pasquier, MD, PhD</b>	Univ Lille, INSERM 1171, CHU, Centre Mémoire (CMRR) Distalz, Lille, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Olivier Hanon, MD, PhD</b>	Service de Gériatrie, Université Paris Descartes, Hôpital Broca, Paris, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Claire Paquet, MD, PhD</b>	Université de Paris, Centre de Neurologie Cognitive Hôpital Lariboisière, INSERMU1144, Paris, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Audrey Gabelle, MD, PhD</b>	Clinical and Research Memory Center of Montpellier, Department of Neurology, Gui de Chauliac Hospital, University of Montpellier, INSERM U1061, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Mathieu Ceccaldi, MD, PhD</b>	CMRR PACA Ouest CHU Timone APMH & Aix Marseille Univ INSERM INS Inst Neurosci Syst, Marseille, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Cédric Annweiler, MD, PhD</b>	Department of Geriatric Medicine, Angers University Hospital, Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, University of Angers, France; Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Pierre Krolak-Salmon, MD, PhD</b>	Univ. Lyon, INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Centre Mémoire Ressource et Recherche de Lyon (CMRR), Hôpital des Charpennes, Hospices Civils de Lyon, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Yannick Béjot, MD, PhD</b>	Univ. Bourgogne, EA7460, Centre Mémoire de Ressources et de Recherches, CHU Dijon Bourgogne, Dijon, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Catherine Belin, MD, PhD</b>	Service de Neurologie Hôpital Saint-Louis AP-HP, Paris, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>David Wallon, MD, PhD</b>	Univ. Normandie, UNIROUEN, INSERM U1245, Département de Neurologie, CNR-MAJ, CHU de Rouen, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data

## Appendix (continued)

Name	Location	Contribution
<b>Mathilde Sauvee, MD, PhD</b>	CMRR Grenoble Arc Alpin, CHU Grenoble, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Emilie Beauflis, MD, PhD</b>	CMRR, University Hospital Tours, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Isabelle Bourdel-Marchasson, MD, PhD</b>	Centre de Résonance Magnétique des Systèmes Biologiques, UMR 5536 Université de Bordeaux; Pole de Gériatrie Clinique CHU de Bordeaux, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Isabelle Jalenques, MD, PhD</b>	Memory Resource and Research Centre of Clermont-Ferrand, CHU de Clermont-Ferrand, and Clermont Auvergne University, Clermont-Ferrand, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data
<b>Marie Chupin, PhD</b>	CATI Multicenter Neuroimaging Platform; Institut du Cerveau et de la Moelle Épineuse, INSERM, U 1127, 3 CNRS, UMR 7225, Sorbonne Université, CATI, Paris, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design
<b>Geneviève Chêne, MD, PhD</b>	Univ. Bordeaux, INSERM, UMR 1219, INSERM, CIC1401-EC; Pole de Sante Publique Centre Hospitalier Universitaire (CHU) de Bordeaux, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
<b>Carole Dufouil, PhD</b>	Univ. Bordeaux, INSERM, UMR 1219, INSERM, CIC1401-EC; Pole de Sante Publique Centre Hospitalier Universitaire de Bordeaux, France	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data

## Appendix 2 Coinvestigators

Coinvestigators are listed at [www.com/WNL/B459](http://www.com/WNL/B459)

## References

1. Chatterjee S, Peters SAE, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. *Diabetes Care*. 2016;39(2):300-307.
2. Rawlings AM, Sharrett AR, Albert MS, et al. The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia: the ARIC study. *Diabetes Care*. 2019;42(7):1248-1254.
3. Mayeda ER, Whitmer RA, Yaffe K. Diabetes and cognition. *Clin Geriatr Med*. 2015;31(1):101-ix.
4. Verdile G, Fuller SJ, Martins RN. The role of type 2 diabetes in neurodegeneration. *Neurobiol Dis*. 2015;84:22-38.
5. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. *Nat Rev Endocrinol*. 2018;14(10):591-604.
6. Willette AA, Bendlin BB, Starks EJ, et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. *JAMA Neurol*. 2015;72(9):1013-1020.

7. Bharadwaj P, Wijesekara N, Liyanapathirana M, et al. The link between type 2 diabetes and neurodegeneration: roles for amyloid- $\beta$ , amylin, and tau proteins. *J Alzheimers Dis*. 2017;59(2):421-432.
8. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. *Diabetes Care*. 2013;36(12):4036-4042.
9. Schneider AL, Selvin E, Sharrett AR, et al. Diabetes, prediabetes, and brain volumes and subclinical cerebrovascular disease on MRI: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCOS). *Diabetes Care*. 2017;40(11):1514-1521.
10. Marseglia A, Fratiglioni L, Kalpouzos G, Wang R, Bäckman L, Xu W. Prediabetes and diabetes accelerate cognitive decline and predict microvascular lesions: a population-based cohort study. *Alzheimers Dement*. 2019;15(1):25-33.
11. Roberts RO, Knopman DS, Cha RH, et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. *J Nucl Med*. 2014;55(5):759-764.
12. Li W, Risacher SL, Huang E, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative. Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort. *Neurology*. 2016;87(6):595-600.
13. Moran C, Beare R, Phan TG, et al. Type 2 diabetes mellitus and biomarkers of neurodegeneration. *Neurology*. 2015;85(13):1123-1130.
14. Li W, Risacher SL, Gao S, Boehm SL, Elmendorf JS, Saykin AJ. Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid  $\beta$ 1-42 in Alzheimer's Disease Neuroimaging Initiative participants. *Alzheimers Dement*. 2018;10:94-98.
15. Qiu C, Sigurdsson S, Zhang Q, et al. Diabetes, markers of brain pathology and cognitive function: the Age, Gene/Environment Susceptibility-Reykjavik Study. *Ann Neurol*. 2014;75(1):138-146.
16. Wang R, Fratiglioni L, Kalpouzos G, et al. Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: a population-based study. *Alzheimers Dement*. 2017;13(3):247-256.
17. Moran C, Beare R, Wang W, Callisaya M, Srikanth V; Alzheimer's Disease Neuroimaging Initiative (ADNI). Type 2 diabetes mellitus, brain atrophy, and cognitive decline. *Neurology*. 2019;92(8):e823-e830.
18. Dufouil C, Dubois B, Vellas B, et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. *Alzheimers Res Ther*. 2017;9(1):67.
19. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43(11):2412-2414.
20. Hugonot-Diner L. MMS version consensuelle GRECO. In: *La Consultation en Gériatrie*. Masson; 2001:13-20.
21. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. *Neurology*. 1988;38(6):900-903.
22. Thurstone LL. Psychophysical analysis: by L.L. Thurstone, 1927. *Am J Psychol*. 1987;100(3-4):587-609.
23. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment: a clinical test. *Arch Neurol*. 1978;35(6):364-367.
24. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. *Arch Clin Neuropsychol*. 2004;19(2):203-214.
25. Opereto G, Chupin M, Batrancourt B, et al. CATI: a large distributed infrastructure for the neuroimaging of cohorts. *Neuroinformatics*. 2016;14(3):253-264.
26. Ashburner J, Friston KJ. Unified segmentation. *NeuroImage*. 2005;26(3):839-851.
27. Chupin M, Hammers A, Liu RSN, et al. Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation. *NeuroImage*. 2009;46(3):749-761.
28. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage*. 2006;31(3):968-980.
29. Samaille T, Fillon L, Cuingnet R, et al. Contrast-based fully automatic segmentation of white matter hyperintensities: method and validation. *PLoS One*. 2012;7(11):e48953.
30. Fazekas F, Barkhof F, Wahlund LO, et al. CT and MRI rating of white matter lesions. *Cerebrovasc Dis*. 2002;13(suppl 2):31-36.
31. Habert M-O, Marie S, Bertin H, et al. Optimization of brain PET imaging for a multicentre trial: the French CATI experience. *EJNMMI Phys*. 2016;3(1):6.
32. Buchert R, Wilke F, Chakrabarti B, et al. Adjusted scaling of FDG positron emission tomography images for statistical evaluation in patients with suspected Alzheimer's disease. *J Neuroimaging*. 2005;15(4):348-355.
33. Toussaint P-J, Perlberg V, Bellec P, et al. Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer's disease using conjoint univariate and independent component analyses. *NeuroImage*. 2012;63(2):936-946.
34. Habert M-O, Bertin H, Labit M, et al. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. *Ann Nucl Med*. 2018;32(2):75-86.
35. de Medeiros K, Robert P, Gauthier S, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. *Int Psychogeriatr*. 2010;22(6):984-994.
36. Sanfilippo MP, Benedict RHB, Zivadinov R, Bakshi R. Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. *NeuroImage*. 2004;22(4):1732-1743.
37. Bollen KA. *Structural Equations with Latent Variables*. John Wiley & Sons; 2014:474.
38. Rosseel Y, Lavaan: an R package for structural equation modeling. *J Stat Softw*. 2012;48(1):1-36.
39. Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. *Methods Psychol Res*. 2003;8(2):23-74.
40. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562.
41. VanderWeele TJ. Mediation analysis: a practitioner's guide. *Annu Rev Public Health*. 2016;37:17-32.
42. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing; 2018. R-project.org/.
43. Espeland MA, Bryan RN, Goveas JS, et al. Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the Women's Health Initiative Magnetic Resonance Imaging studies. *Diabetes Care*. 2013;36(1):90-97.
44. Moran C, Beare R, Phan T, et al. Neuroimaging and its relevance to understanding pathways linking diabetes and cognitive dysfunction. *J Alzheimers Dis*. 2017;59(2):405-419.
45. Thambisetty M, Jeffrey Metter E, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. *JAMA Neurol*. 2013;70(9):1167-1172.
46. Benedict C, Grillo CA. Insulin resistance as a therapeutic target in the treatment of Alzheimer's disease: a state-of-the-art review. *Front Neurosci*. 2018;12:215.

# Neurology<sup>®</sup>

## Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort

Eric Frison, Cecile Proust-Lima, Jean-Francois Mangin, et al.

*Neurology* 2021;97:e836-e848 Published Online before print July 1, 2021

DOI 10.1212/WNL.00000000000012440

**This information is current as of July 1, 2021**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/97/8/e836.full">http://n.neurology.org/content/97/8/e836.full</a>
<b>References</b>	This article cites 43 articles, 11 of which you can access for free at: <a href="http://n.neurology.org/content/97/8/e836.full#ref-list-1">http://n.neurology.org/content/97/8/e836.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Alzheimer's disease</b> <a href="http://n.neurology.org/cgi/collection/alzheimers_disease">http://n.neurology.org/cgi/collection/alzheimers_disease</a> <b>Cognitive aging</b> <a href="http://n.neurology.org/cgi/collection/cognitive_aging">http://n.neurology.org/cgi/collection/cognitive_aging</a> <b>Cohort studies</b> <a href="http://n.neurology.org/cgi/collection/cohort_studies">http://n.neurology.org/cgi/collection/cohort_studies</a> <b>MRI</b> <a href="http://n.neurology.org/cgi/collection/mri">http://n.neurology.org/cgi/collection/mri</a> <b>PET</b> <a href="http://n.neurology.org/cgi/collection/pet">http://n.neurology.org/cgi/collection/pet</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

